Prevention Of Cardiac Transplant Rejection — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for prevention of cardiac transplant rejection. 52 active patents protecting 3 drugs from 3+ originators. First major cliff: 2039. Daily refresh.

3
Approved drugs
52
Active US patents
65/100
Avg vulnerability
$3.5B
Annual revenue covered

Originators in Prevention Of Cardiac Transplant Rejection

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Astellas Pharma 30 patents Novartis AG (originally Sandoz) 17 patents Roche Palo 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating prevention of cardiac transplant rejection. Each bar = one year. Y-axis scaled to peak year (30 patents).

1
27
30
28
1
29
1
30
1
31
1
32
3
33
2
34
1
36
3
37
1
38
6
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Prograf
TACROLIMUS
 Astellas Pharma 30 70 $1.6B 2028-05-30
Sandimmune
cyclosporine
 Novartis AG (originally Sandoz) 17 55 $1.9B 2027-11-03
Cellcept
MYCOPHENOLATE MOFETIL
 Roche Palo 5 71 — 2039-08-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12083103 Prograf method of use 88 2028-05-30
12083103 Prograf method of use 88 2028-05-30
12083103 Prograf method of use 88 2028-05-30
11110081 Prograf method of use 75 2028-05-30
10864199 Prograf method of use 75 2028-05-30
10864199 Prograf method of use 75 2028-05-30
11123331 Prograf method of use 75 2028-05-30
10864199 Prograf method of use 75 2028-05-30
11123331 Prograf method of use 75 2028-05-30
11123331 Prograf method of use 75 2028-05-30

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10918694 Sandimmune formulation 42 2037-02-28
9669974 Sandimmune formulation 42 2034-05-11
9676525 Sandimmune formulation 42 2034-02-07
10441630 Sandimmune formulation 42 2033-08-23
8561859 Sandimmune formulation 48 2032-04-16
8292129 Sandimmune formulation 48 2031-02-25
9132071 Sandimmune formulation 48 2029-06-02
10813976 Sandimmune formulation 50 2037-09-22
12097284 Cellcept formulation 55 2039-08-16
10166190 Prograf formulation 55 2028-05-30

Related